Search





Search





Markets
/
Stocks
/
nasdaq-xbio
/

Xenetic Biosciences Inc

XBIO

Add to Watchlist

3.044USD

-0.130-4.18%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

6.97MMarket Cap

LossP/E TTM



Xenetic Biosciences Inc

3.044

-0.130-4.18%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Xenetic Biosciences Inc

Currency: USD Updated: 2026-05-15

Key Insights

Xenetic Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 187 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 0.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Xenetic Biosciences Inc's Score

Industry at a Glance

Industry Ranking

187 / 382

Overall Ranking

349 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Xenetic Biosciences Inc Highlights

StrengthsRisks

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 17.18% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.98M.

Undervalued

The company’s latest PE is -2.56, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 178.51K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Xenetic Biosciences Inc is 9.27, ranking 6 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 806.92K, representing a year-over-year increase of 36.01%, while its net profit experienced a year-over-year increase of 49.47%.

Score

Industry at a Glance

Previous score

9.27

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.71

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Xenetic Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Xenetic Biosciences Inc is 8.08, ranking 62 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.56, which is -74.14% below the recent high of -0.66 and -102.44% above the recent low of -5.18.

Score

Industry at a Glance

Previous score

8.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 187/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for Xenetic Biosciences Inc. The Biotechnology & Medical Research industry's average is 8.13.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Xenetic Biosciences Inc is 6.31, ranking 263 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.40 and the support level at 2.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.024

Neutral

RSI(14)

48.649

Neutral

STOCH(KDJ)(9,3,3)

34.405

Neutral

ATR(14)

0.177

High Vlolatility

CCI(14)

-25.358

Neutral

Williams %R

72.727

Sell

TRIX(12,20)

-0.004

Sell

StochRSI(14)

8.312

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.100

Sell

MA10

3.091

Sell

MA20

3.096

Sell

MA50

3.027

Buy

MA100

2.656

Buy

MA200

2.929

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Xenetic Biosciences Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.97%, representing a quarter-over-quarter decrease of 53.00%. The largest institutional shareholder is James Simons, holding a total of 178.51K shares, representing 7.79% of shares outstanding, with 348.95% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Renaissance Technologies LLC

Star Investors

178.51K

CLS Therapeutics, Ltd.

147.50K

Genkin (Dmitry Dmitrievich)

68.46K

Vinogradov (Alexey Andreevich)

18.68K

Citadel Advisors LLC

14.88K

DRW Securities, LLC

13.82K

Geode Capital Management, L.L.C.

13.58K

+27.12%

The Vanguard Group, Inc.

Star Investors

6.73K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Xenetic Biosciences Inc is 1.12, ranking 332 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.